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Abstract 
Purpose: Identification of effective and reliable biomarkers that could be used to predict the efficacy of 
endocrine therapy are of crucial importance to the management of oestrogen receptor positive (ER+) breast 
cancer (BC). KIF18A, a key regulator of cell cycle, is overexpressed in many human cancers, including BC. In 
this study, we investigated the role of KIF18A as a biomarker to predict the benefit from endocrine treatment in 
early ER+ BC patients. 
Methods: KIF18A expression was assessed at the genomic level using the METABRIC dataset to explore its 
prognostic and predictive value in ER+ BC patients (n=1506). Predictive significance of KIF18A mRNA was 
validated using KM-Plot datasets (n=2061). KIF18A protein expression was assessed using 
immunohistochemistry in a large annotated series of early-stage ER+ BC (n=1592) with long-term follow-up. 
Results: High mRNA and protein expression of KIF18A were associated with short recurrence free survival 
(RFS), distant metastasis free survival (DMFS) and BC specific survival (BCSS) (all P<0.05) in ER+ BC in 
patients who received no adjuvant treatment or adjuvant endocrine therapy. In multivariate analysis, high 
KIF18A expression was an independent prognostic biomarker for poor RFS (P=0.027) and DMFS (P=0.028) in 
patients treated with adjuvant endocrine therapy. 
Conclusion: KIF18A appears to be a candidate biomarker of a subgroup of ER+ BC characterised by poor 
clinical outcome. High KIF18A expression has prognostic significance to predict poor benefit from endocrine 
treatment for patients with ER+ BC. Therefore, measurement of KIF18A on ER+ BC patients prior to treatment 
could guide clinician decision on benefit from endocrine therapy. 
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Introduction 
Oestrogen receptor (ER) is the driving transcription factor in up to three-quarters of all BC and its protein 
expression by immunohistochemistry classifies patients as either having ER+ or ER-negative (ER–) disease. 
Endocrine therapy is one of the most effective and well-established targeted anticancer treatments for ER+ BC. 
However, despite its undisputed efficacy, up to one-third of patients will relapse after treatment for early-stage 
disease, while in the advanced setting, all will eventually progress [1]. It is therefore desirable to be able to 
predict, at an early stage of treatment, which ER+ patients will benefit from endocrine therapy [2]. The 
identification of biomarkers to predict endocrine therapy benefit in addition to ER status is therefore of crucial 
importance in stratifying ER+ patients for targeted therapy. 
KIF18A, a member of kinesin-8 family, plays pivotal roles in regulating microtubule dynamics, chromosome 
congression and cell division [3]. KIF18A is involved in several cancers: breast, colorectal and hepatocellular 
cancers, and cholangiocarcinoma [4-7] particularly driving proliferation, migration and anoikis in BC [4]. 
KIF18A protein expression is over expressed in BC compared with normal breast and it has been proposed as a 
useful predictive marker for lymph node metastasis [8]. In additional, ER is a putative cargo for KIF18A, and 
presents a novel interaction between them that may have important physiological and pharmacological 
implications for oestrogen action in various cells [9, 10].  
Both oestrogen and ER can up-regulate the expression of KIF18A mRNA and protein in vivo and in vitro 
suggesting that KIF18A may be associated with ER-related cancers [10]. Nevertheless, the prognostic power of 
KIF18A in ER+ BC and its relation with endocrine therapy efficacy has not been reported. In this study, we 
explore the possibility of KIF18A as a biomarker for the prognosis of ER+ BC patients and as a predictor of 
endocrine response.  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Method 
KIF18A mRNA expression 
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [11], comprising 1,506 ER+ 
BC, was used to analyse and explore the prognostic value of KIF18A in ER+ BC patients and its role as 
predictive biomarker of benefit from endocrine treatment. In the METABRIC study, DNA and RNA extracted 
from primary tumour samples were hybridised using Affymetrix SNP 6.0 arrays (Affymetrix, Inc., Santa Clara, 
USA) and Illumina Human HT-12 v3 platforms (Illumina, Inc., San Diego, USA). Kaplan Meier Plotter-Breast 
Cancer (KM-Plotter) software [12], was used to validate the prognostic and predictive value of KIF18A mRNA 
expression, this dataset contains mRNA expression for 2,061 patients with ER+ BC. 
KIF18A protein expression 
KIF18A protein expression was assessed in a large well-characterised cohort of ER+, early stage primary 
operable invasive BC patients, aged ≤ 70 years (n= 1592). Patients presented at Nottingham City Hospital 
between 1989 and 2006. Clinical history, tumour characteristics, information on therapy and outcomes are 
prospectively maintained. The clinic-pathological parameters for the cohort series are summarised in Table 1. 
Western blotting 
Primary antibody specificity of KIF18A 1:500 (HPA039484, Sigma-Aldrich, UK) was validated by Western 
blotting using MDA-MB-436 human BC cell line (American Type Culture Collection; Rockville, MD, USA). 
Proteins were detected using IRDye 800CW and 600RD fluorescent secondary antibodies (1:15 000 dilution. 
926-32213 and 926-68072, LI-COR Biosciences) and visualised using the Odyssey Fc with Image Studio 4.0 
(LI-COR Biosciences). Anti-β-actin primary antibody (Sigma-Aldrich) was used as a loading control (1:5000). 
A specific band for KIF18A was visualised at the correct predicted size (102 kDa; Fig. 1A). 
Tissue arrays and Immunohistochemistry 
Tumour samples were arrayed as previously described [13]. Immunohistochemical staining was performed on 4 
µm TMA sections using Novolink polymer detection system (Leica Biosystems, RE7150-K). Briefly, tissue 
slides were deparaffinised with xylene and rehydrated through three changes of alcohol. Heat-induced antigen 
epitope retrieval was performed in citrate buffer (pH 6.0) for 20 minutes using a microwave oven (Whirpool 
JT359 Jet Chef 1000W). Endogenous peroxidase activity was blocked by Peroxidase Block for 5 minutes. 
Slides were washed with Tris-Buffered Saline (TBS, pH 7.6), followed by application of Protein Block for 5 
minutes. Following another TBS wash, sections were incubated, for overnight at 4 °C, with the primary KIF18A 
antibody diluted at 1:300 in Leica antibody diluent (RE AR9352, Lieca, Biosysytems, UK). Slides were washed 
with TBS followed by incubation with Post Primary Block for 30 minutes followed by a TBS wash. Novolink 
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polymer was applied for 30 minutes. 3,3'-diaminobenzidine (DAB) chromogen was applied for 5 minutes. 
Slides were counterstained with Novolink haematoxylin for 6 minutes, dehydrated and cover-slipped. 
Stained TMA sections were assessed using high-resolution digital images (Nanozoomer, Hamamatsu Photonics) 
and viewing software (Xplore; Philips, UK). Evaluation of staining for KIF18A was based on a semiquantitative 
assessment of immunoreactivity using a modified histochemical score (H-score), which includes an assessment 
of both the intensity and the percentage of stained cells [14]. Staining intensity was assessed as follows 0= 
negative; 1= weak; 2= moderate; 3= strong and the percentage of the positively stained tumour cells was 
estimated subjectively. The final H-score was calculated multiplying the percentage of positive cells (0–100) by 
the intensity (0–3), producing a total range of 0–300. For KIF18A protein expression, the cut-off was an H-score 
of 80 determined using X-Tile (X-Tile Bioinformatics Software, Yale University, version 3.6.1), with the 
samples stratified to high and low expression groups based on patient outcome. 
Clinical outcome 
The primary outcomes were recurrence free survival (RFS), defined as the time in months from surgery until 
developing local or regional recurrence, distant-metastases free survival (DMFS), defined as the time in months 
from surgery until developing distant-metastasis, and BC specific survival (BCSS), defined as the time in 
months from the date of primary surgery to the date of BC-related death, and their association with tamoxifen 
efficacy. Secondary outcomes included associations with clinicopathological factors. 
Statistical analysis 
Statistical analysis was performed using SPSS 24.0 statistical software (SPSS Inc., Chicago, IL, USA). The 
analysis for this study compared the low and high expression of KIF18A. For the continuous variables, 
differences between three or more groups were assessed using one-way analysis of variance (ANOVA) with the 
post-hoc Tukey multiple comparison test. Spearman’s correlation coefficient was carried out to examine the 
association between two continuous variables. The Chi-square test was performed for inter-relationships 
between categorical variables. Kaplan-Meier and log-rank analysis were used to assess RFS, DMFS and BCSS. 
Hazard ratios and confidence intervals were calculated from univariate Cox regression survival analysis. 
Multivariate Cox Regression analysis with adjustment of covariates was used to identify independent prognostic 
biomarkers. Benjamini–Hochberg procedure for multiple test correction was performed. P value of ≤ 0.05 was 
considered significant. 
Result 
KIF18A expression in ER+ BC 
KIF18A protein expression was observed, predominantly in the nucleus of invasive BC cells, with expression 
levels varying from absent to high (Fig. 1B and 1C). High KIF18A mRNA expression was observed in 987/1506 
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(65.5%) of the METABRIC cohort and KIF18A protein expression was observed in 213/406 (52%) of cases of 
Nottingham cohort. 
KIF18A expression and clinicopathological parameters 
High KIF18A mRNA expression was significantly associated with poor Nottingham Prognostic Index (NPI) (P< 
0.0001, Fig. 2A), higher tumour grade (P< 0.0001, Fig. 2B) and larger tumour size (P=0.0002). However, 
KIF18A protein expression showed no statistical significance association with grade, tumour size or NPI. 
KIF18A prognosis in ER+ BC 
High expression of KIF18A was highly associated with poor clinical outcome in ER+ BC patients. Specifically, 
KIF18A mRNA overexpression was associated with poor RFS (P=0.00013), DMFS (P=0.00003) and BCSS 
(P=0.000008) in ER+ BC using the METABRIC dataset (Fig 3A, 3C and 3E). These observations were 
confirmed in the KM-Plotter cohort: RFS (P=2.1x10-10), DMFS (P=1.1x10-6) and BCSS (P= 4.0x10-8) 
(Supplementary Fig. 1A-C). 
The above findings at the gene expression level were confirmed at the protein level where high KIF18A protein 
in tumours was significantly associated with a shorter RFS (P=0.00003), and DMFS (P=0.003) together with 
poor BCSS (P=0.002) compared with the low expression group, which showed better clinical outcome (Fig. 3B, 
3D and 3F). 
KIF18A is a predictive biomarker of resistance to endocrine therapy 
Since high expression of KIF18A confers poor clinical outcome in patients with ER+ BC, we hypothesised that 
KIF18A may play a potential role in hormone therapy resistance. To validate this hypothesis, we compared the 
association of KIF18A expression with RFS, DMFS and BCSS in two sub-populations of ER+ BC (untreated vs 
endocrine-treated). 
In patients who received endocrine therapy, tumours with high KIF18A mRNA expression had a poor RFS 
(P=0.007) and DMFS (P=0.004) (Fig. 4B and 4D) in comparison to patients with low mRNA expression of 
KIF18A. A similar observation was seen in patients who did not receive any adjuvant treatment: RFS (P= 0.001) 
and DMFS (P= 0.014) (Fig 4A and 4C), In addition, high KIF18A mRNA was a predictive of long term short 
BCSS in those treated with endocrine therapy (P=0.016, Fig. 4F) but not in those patients not receiving any 
adjuvant therapy (P=0.075, Fig. 4E).  
These observations were confirmed in the KM-Plotter dataset where patients who had high KIF18A mRNA and 
received endocrine therapy had a poor RFS (P=1.4x10-5), DMFS (P= 8.3x10-6) and BCSS (P=0.018) 
(Supplementary Fig 2B, D and F). This was similar to those patients who did not receive any adjuvant therapy 
where high KIF18A mRNA expression was associated with poor RFS (P=0.0012), DMFS (P=0.0026) and short 
BCSS (P=0.0053) (Supplementary Fig. 2A, C and E). 
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These results were validated at the protein level where high KIF18A protein was significantly associated with 
poor RFS (P=0.00001), DMFS (P=0.004) and BCSS (P=0.001) in patients who had endocrine therapy (Fig 5B, 
D and F). In untreated patients, high KIF18A was predictive of a poor RFS (P=0.001), DMFS (P=0.036) and 
short BCSS (P= 0.042) (Figure 5A, C and E). 
KIF18A expression in ER+ BC is an independent prognostic factor 
Multivariate analysis of KIF18A mRNA expression in ER+ BC demonstrated that KIF18A expression was an 
independent prognostic factor for RFS (P=0.01), DMFS (P=0.04) and BCSS (P=0.03) Table 2. The same 
observations were demonstrated with KIF18A protein levels: RFS (P=0.00001), DMFS (P=0.005) and BCSS 
(P=0.02), Table 3.  
In patients who received endocrine therapy, KIF18A mRNA expression was not independent of tumour grade, 
tumour size and nodal stage, Table 4. However, KIF18A protein expression remained an independent predictive 
factor of poor RFS (P=0.027) and DMFS (p=0.028) and short BCSS (P=0.050), in those patients who were 
treated with endocrine therapy Table 5. 
Discussion 
Over the last two decades anti-oestrogenic strategies have resulted in a paradigm shift in the treatment of BC. 
Endocrine therapies now represent the cornerstone of systemic treatment for women with ER+ tumours at every 
stage of management. For adjuvant therapy of ER+ BC, tamoxifen improves overall survival and reduces risk 
for development of BC [15]. However, an unpredictable subset of patients who received adjuvant endocrine 
therapy will relapse and die as a result of the disease [2]. Therefore, prediction of those patents that may or may 
not benefit from adjuvant endocrine therapy would be beneficial for ER+ BC patients. 
KIF18A, is a member of the kinesin 8 family and a key regulator of cell cycle, has been demonstrated to play 
important roles in chromosome alignment during mitosis [3, 16, 17]. Several studies have revealed that KIF18A 
upregulation may affect the biological characteristics of cancer cells [5-7]. Nevertheless, the prognostic power 
of KIF18A in ER+ BC and its relation with endocrine therapy have not been reported before. This study shows 
that high KIF18A mRNA expression is associated with poor prognostic factors in ER+ BC which in consistent 
with a previous study that suggested KIF18A may play an important role in human BC carcinogenesis and 
KIF18A overexpression is associated with tumour grade, metastasis and poor survival [4]. 
Zusev and Benayahu (2009) reported that both oestrogen and ER could up-regulate the expression of KIF18A 
mRNA and protein, suggesting that KIF18A may be associated with ER-related cancers [10]. Our study is the 
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first to show that high expression of KIF18A at both the mRNA and protein levels are highly associated with 
poor outcome in ER+ BC. Thus its high levels was associated with poor RFS, DMFS and BCSS, and these 
results indicate its role as a poor prognostic biomarker of ER+ BC. 
Previous studies report a novel interaction between KIF18A and ER where MBA-15 cells treated by oestrogen 
express higher levels of KIF18A mRNA, which demonstrates involvement of KIF18A in ER signalling [9, 10]. 
Further, inhibition of KIF18A expression significantly inhibits the proliferative capability of BC cells in vitro 
and in vivo, and decreases cancer cell migration by stabilising MTs at leading edges and ultimately induces 
anoikis of cells with inactivation of the PI3K signalling pathway [4]. To our knowledge, dysregulation of cell 
cycle checkpoints is common in cancer and promote antiestrogen resistance in ER+ BC [18]. However, the 
association between KIF18A overexpression and relapse with endocrine therapy in patients with ER+ BC has 
previously not been investigated. Our results show the significant predictive power of KIF18A in ER+ BC 
particularly where high levels of KIF18A is correlated with poor RFS and DMFS after endocrine therapy. 
KIF18A expression appears to be a candidate marker of a subgroup of ER+ BC characterised by poor outcome 
in those patients treated with endocrine therapy. 
The American Society of Clinical Oncology (ASCO) guidelines for ER measurement attempts to make the 
benefit of endocrine therapy available to the widest range of patients, by recommending 1% as universal cut 
point to distinguish between ER positivity and negativity to help determine likelihood of patients responding to 
endocrine therapy [19]. However, this might lead to overtreatment and unnecessary endocrine therapies with the 
potential of causing more harm than good for patients with ER+ BC, who will resist and fail to respond to 
endocrine therapy and eventually will relapse. Therefore, we conclude that KIF18A expression has the potential 
to predict those who might fail to benefit from endocrine therapy.  
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Figure 1: Western blotting result for A) KIF18A expression in MDA-MB-436 BC cell lysates. KIF18A protein 
expression in invasive BC cores B) Negative IHC expression and C) Positive IHC expression 
Figure 2: KIF18A mRNA expression and its association with A) NPI and B) tumour grade 
Figure 3: High KIF18A expression as a prognostic biomarker of poor clinical outcome in patients with ER+ 
BC. Kaplan–Meier survival plots for A) Recurrence C) Distant metastasis and E) Breast cancer specific 
survival, comparing high and low groups of KIF18A mRNA expression. Kaplan–Meier survival plots for B) 
Recurrence, D) Distant metastasis and F) Breast cancer specific survival for expression of KIF18A protein 
levels. 
Figure 4: KIF18A mRNA expression as a prognostic biomarker for poor clinical outcome in untreated patients 
with ER+ BC A) Recurrence C) Distant metastasis E) Breast cancer specific survival. KIF18A mRNA 
expression as a predictive biomarker for poor benefit from endocrine therapy in patients with ER+ BC B) 
Recurrence D) Distant metastasis F) Breast cancer specific survival. 
Figure 5: KIF18A protein expression as a prognostic biomarker for poor clinical outcome in untreated patients 
with ER+ BC A) Recurrence C) Distant metastasis E) Breast cancer specific survival. KIF18A protein 
expression as a predictive biomarker for poor benefit from endocrine therapy in patients with ER+ BC B) 
Recurrence D) Distant metastasis F) Breast cancer specific survival. 
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Table 1: Clinicopathological characteristics of ER+ BC cohort. 
Clinic-pathological 
characteristics
METABRIC cohort Nottingham cohort
No. (%) No. (%)
Tumour size (cm) 
<2 cm 
≥2 cm 
Grade 
1 
2 
3 
Nottingham Prognostic Index 
GPG 
MPG 
PPG 
Endocrine therapy 
No 
Yes 
Other 
Nodal Stage 
1 
2 
3 
PR 
Negative 
Positive
475 (31.5) 
1031 (68.5) 
166 (11.5) 
707 (49.1) 
565 (38.4) 
623 (41.3) 
772 (51.2) 
111 (7.5) 
234 (15.5) 
384 (25.5) 
888 (59) 
404 (36.2) 
634 (56.8) 
78 (7) 
486 (23.2) 
1020 (76.8)
806 (55.7) 
640 (44.3) 
388 (24.7) 
661 (42.1) 
522 (33.2) 
598 (41.4) 
668 (46.1) 
180 (12.5) 
884 (55.7) 
558 (35) 
149 (9.3) 
1025 (65.1) 
439 (27.9) 
111 (7) 
300 (21.3) 
1103 (78.7)
GPG: Good prognostic group; MPG: Moderate prognostic group; PPG: Poor prognostic group
Table 2: Multivariate analysis of associations between KIF18A mRNA expression and clinicopathological 
parameters in ER+ BC patients. 
Parameters Recurrence free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
3.308 (1.568-6.979) 
1.223 (0.868-1.723) 
1.106 (0.769-1.590) 
1.359 (0.856-2.159)
0.002 
0.250 
0.587 
0.194
0.01 
0.41 
0.73 
0.48
Distant metastasis free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
2.887 (1.301-6.410) 
1.406 (0.952-2.075) 
1.397 (0.959-2.035) 
1.878 (1.109-3.179)
0.009 
0.087 
0.081 
0.019
0.04 
0.1 
0.1 
0.04
Breast cancer specific survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
3.729 (1.332-10.439) 
1.897 (1.193-3.016) 
1.375 (0.917-2.062) 
1.842 (1.028-3.302)
0.012 
0.007 
0.123 
0.040
0.03 
0.03 
0.15 
0.06
P*: Adjusted p-value
Table 3: Multivariate analysis of associations between KIF18A protein expression and clinicopathological 
parameters in ER+ BC patients. 
Parameters Recurrence free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.897 (1.375-2.617) 
0.892 (1.088-1.387) 
1.529 (1.211-1.932) 
1.176 (0.868-1.594)
0.00000
9 
0.346 
0.0003 
0.294
0.00001 
0.43 
0.0008 
0.49
Distant metastasis free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.701 (1.216-2.379) 
1.374 (1.081-1.748) 
1.825 (1.428-2.331) 
1.498 (1.079-2.080)
0.002 
0.010 
0.00000
1 
0.016
0.005 
0.016 
0.00001 
0.02
Breast cancer specific survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.616 (1.137-2.299) 
1.408 (1.088-1.1822) 
1.735 (1.337-2.250) 
1.357 (0.959-1.929)
0.008 
0.009 
0.00003 
0.85
0.02 
0.015 
0.0002 
1.06
P*: Adjusted p-value
Table 4: Multivariate analysis of associations between KIF18A mRNA expression and clinicopathological 
parameters in endocrine-treated patients. 
Parameters Recurrence free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
2.624 (1.033-6.664) 
1.144 (0.728-1.798) 
1.087 (0.685-1.725) 
0.999 (0.658-1.519)
0.042 
0.559 
0.723 
0.922
0.21 
1.39 
1.20 
1.15
Distant metastasis free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
2.449 (0.957-6.267) 
1.255 (0.769-2.049) 
1.413 (0.884-2.258) 
1.354 (0.718-2.552)
0.062 
0.363 
0.149 
0.349
0.31 
0.45 
0.37 
0.58
P*: Adjusted p-value
Table 5: Multivariate analysis of associations between KIF18A protein expression and clinicopathological 
parameters in endocrine-treated patients. 
Parameters Recurrence free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.790 (1.143-2.804) 
1.463 (0.998-2.145) 
1.805 (1.253-2.602) 
0.999 (0.658-1.519)
0.011 
0.051 
0.002 
0.998
0.027 
0.085 
0.01 
1.24
Distant metastasis free survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.729 (1.104-2.709) 
2.325 (1.622-3.333) 
2.814 (2.050-3.862) 
1.223 (0.789-1.897)
0.017 
0.000004 
1.52e-10 
0.368
0.028 
0.00001 
< 0.00001 
0.46
Breast cancer specific survival
HR (95% CI) P P*
KIF18A 
Grade 
Nodal Stage 
Tumour size
1.702 (1.054-2.748) 
1.780 (1.166-2.716) 
1.933 (1.307-2.859) 
1.050 (0.664-1.660)
0.030 
0.007 
0.001 
0.836
0.050 
0.017 
0.005 
1.04
P*: Adjusted p-value
